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Thehypoxia and profound inflammatory 
response associated with the pneumoniti-
sobserved with the SARS- CoV-2 virus respon-
sible for the recent COVID-19 pandemic has 
overwhelmed intensive care facilities in the 
epicenters of infection including Wuhan, 
China, Northern Italy and in the USA, the 
Seattle and New York City areas. The Society 
for Immunotherapy of Cancer (SITC) stands 
along with and supports our colleagues in 
emergency departments, intensive care units 
(ICUs) and inpatient wards in the global effort 
to overcome this unprecedented pandemic. It 
is becoming apparent that the ‘ground glass’ 
infiltrative appearance seen on CT scans from 
patients with COVID-19 with pneumonitis is 
reminiscent of imaging from patients with 
immune checkpoint inhibitor (ICI)- induced 
pneumonitis.1 2 Additionally, elevated inter-
leukin-6 (IL-6) is a hallmark inflammatory 
signature seen in serum of patients with severe 
COVID-19 acute respiratory distress.3 Many of 
us have experience with the administration of 
immune- modulatory agents, which is why the 
cancer immunotherapy community is poised 
to contribute to the current fight against 
COVID-19.
One possibility is to encourage the use of IL-6 
or IL-6- receptor (IL- 6R) blocking antibodies like 
tocilizumab (ActemraTM, Roche- Genentech), 
sarilumab (KevzaraTM, Regeneron) and siltux-
imab (SylvantTM, EUSA Pharma) that are Food 
and Drug Administration (FDA) approved for 
various conditions, including rheumatological 
disease and the lymphoproliferative disorder 
Castleman’s syndrome. These agents could 
be used on easily and immediately available 
compassionate use protocols that could be 
approved on an emergency basis by all insti-
tutional review boards (IRBs) around the 
world for critically ill patients with COVID-19- 
induced hypoxia. Tocilizumab also is already 
FDA approved to manage cytokine release 
syndrome (CRS) in patients receiving chimeric 
antigen receptor T cell therapy.4 5 In addi-
tion, tocilizumab has been shown to reduce 
toxicity in patients treated with ICIs who were 
steroid refractory,6 and has been added to the 
ICI agents ipilimumab and nivolumab in an 
ongoing US phase II study (NCT03999749) to 
ameliorate immune- related toxicity. In Castle-
man’s disease, a lymphoproliferative disorder 
caused by Kaposi’s Sarcoma Herpesvirus, a 
pathogen that produces viral IL-6, tocilizumab 
has been shown to reduce viral loads.7 Tocili-
zumab is also being explored as a potential 
supportive care measure for the management 
of CRS in patients with cancer treated with a 
number of CD3- based bispecific molecules. 
Now, data from the frontlines of the pandemic 
indicates that the agent may offer lifesaving 
benefit for COVID-19 patients with respiratory 
distress.
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Emerging evidence suggests that high levels of C reactive 
protein (CRP) and IL-6 are observed in patients infected 
with COVID-19.1 8 Anecdotal experience on the use of 
tocilizumab at doses comparable to those used for the 
management of CRS from investigators in Italy9 and from 
China10 has reported rapid improvement in both intu-
bated and non- intubated patients. In these reports, expe-
ditious administration of anti- IL- 6R therapy for patients in 
acute respiratory distress has been critical. A recent study 
protocol to evaluate the efficacy of tocilizumab in COVID-
19- induced pneumonitis accrued over 300 patients world-
wide in less than 24 hours. Additionally, Genentech will 
also provide 10 000 vials of tocilizumab to the US Strategic 
National Stockpile.11 Tocilizumab was also approved in 
China in March 2020, for the treatment of patients with 
COVID-19 with serious lung damage and elevated IL-6. 
Sponsors, investigators and regulators have moved with 
unprecedented speed and collaboration to initiate proto-
cols to formally study the safety and efficacy of antiviral 
agents and vaccines, as well as various anti- IL-6 antibodies 
in patients with COVID-19. In the USA, a trial of sarilumab 
in the COVID-19 setting is ongoing.12
Although randomized data definitively showing that 
IL- 6R blockade benefits patients with COVID-19- induced 
pneumonitis are currently lacking, we propose that an 
effort should be made to maximize the availability of anti- 
IL-6 agents, includingtocilizumab and sarilumab for use 
on a compassionate basis to critically illhospitalized SARS- 
CoV-2- infected patients during this extraordinary situation. 
In addition, consideration should be given to focus efforts 
on rapidly expanding the ability of clinicians and clinical 
investigators to access investigational anti- IL-6 agents, in 
particular for those agents where phase 1 and/or phase 
2 studies have been completed, and acceptable safety has 
been demonstrated. Even if the primary impact of a single 
dose of these drugs is to accelerate recovery and get patients 
off ventilator support and out of the ICU more rapidly, this 
could significantly decompress our severely overburdened 
healthcare systems. We suggest that straightforward param-
eters including complete blood counts and differentials, 
serum lactate dehydrogenase (LDH), ferritin, CRP and IL-6 
be recorded in treated patients, that serum be retained for 
future analyses, and simple clinical parameters be assessed 
including time in ICU, days of hospitalization and pulmo-
nary parameters, including forced expiratory volume in 1 
s (for non- intubated patients), fractional inspired oxygen 
(FiO2), arterial oxygen tension/FiO2 ratio and type of 
oxygen supplementation need be recorded pre- anti- IL- 6R 
and post- anti- IL- 6R therapy. A simple compassionate use 
protocol could be assembled from existing templates, 
and all efforts should be made for emergency approval of 
the use of IL- 6R blocking antibodies by local IRBs within 
24 hours of the request being made. Additionally, consid-
eration should be given by pharma and biotech to redirect 
the use of facilities and increase personnel involved in drug 
manufacturing and those serving as liaisons to the front-
lines to facilitate drug availability. Extraordinary times call 
for extraordinary measures, and SITC calls on all involved, 
including pharmaceutical sponsors, health authorities and 
IRBs, to continue to move swiftly and creatively to remove 
barriers and increase access to agents like anti- IL- 6R drugs 
that may improve our care for COVID-19 pneumonitis.
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